Hostname: page-component-55f67697df-gmt7q Total loading time: 0 Render date: 2025-05-24T10:30:21.814Z Has data issue: false hasContentIssue false
  • English
  • Français

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

Published online by Cambridge University Press:  16 April 2020

M. De Hert ,
M. Dobbelaere ,
E.M. Sheridan ,
D. Cohen  and
C.U. Correll
M. De Hert*
Affiliation:
Centre Catholic University Leuven, campus Kortenberg, Leuvensesteenweg 517, 3070Kortenberg, Belgium
M. Dobbelaere
Affiliation:
Psychiatric Centre Catholic, University Leuven, campus Gasthuisberg, Gasthuisberg, Belgium
E.M. Sheridan
Affiliation:
The Zucker Hillside Hospital, Glen Oaks, New York, USA
D. Cohen
Affiliation:
Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Netherlands Division Chronic Care, Noord-Holland-Noord, GGZ-NHN, Heerhugowaard, Netherlands
C.U. Correll
Affiliation:
The Zucker Hillside Hospital, Glen Oaks, New York, USA Albert Einstein College of Medicine, Bronx, New York, USA
*
*Corresponding author. Tel.: +32 2 758 05 11. E-mail address: marc.de.hert@uc-kortenberg.be (M. De Hert).
Get access

Abstract

Second-generation antipsychotics (SGA) are being used more often than ever before in children and adolescents with psychotic and a wide range of non-psychotic disorders. Several SGA have received regulatory approval for some paediatric indications in various countries, but off-label use is still frequent. The aim of this paper was to perform a systematic review and critically evaluate the literature on cardiometabolic and endocrine side-effects of SGA in children and adolescents through a Medline/Pubmed/Google Scholar search of randomized, placebo controlled trials of antipsychotics in children and adolescents (<18 years old) until February 2010. In total, 31 randomized, controlled studies including 3595 paediatric patients were identified. A review of these data confirmed that SGA are associated with relevant cardiometabolic and endocrine side-effects, and that children and adolescents have a high liability to experience antipsychotic induced hyperprolactinaemia, weight gain and associated metabolic disturbances. Only weight change data were sufficiently reported to conduct a formal meta-analysis. In 24 trials of 3048 paediatric patients with varying ages and diagnoses, ziprasidone was associated with the lowest weight gain (−0.04 kg, 95% confidence interval [CI]: −0.38 to +0.30), followed by aripiprazole (0.79 kg, 95% CI: 0.54 to 1.04], quetiapine (1.43 kg, 95% CI: 1.17 to 1.69) and risperidone (1.76 kg, 95% CI: 1.27 to 2.25) were intermediate, and olanzapine was associated with weight gain the most (3.45 kg, 95% CI: 2.93 to 3.97). Significant weight gain appeared to be more prevalent in patients with autistic disorder who were also younger and likely less exposed to antipsychotics previously. These data clearly suggest that close screening and monitoring of metabolic side effects is warranted and that the least cardiometabolically problematic agents should be used first whenever possible. A good collaboration between child- and adolescent psychiatrists, general practitioners and paediatricians is essential to maximize overall outcomes and to reduce the likelihood of premature cardiovascular morbidity and mortality.

Keywords

AdolescentsAntipsychoticsCardiovascular diseaseChildrenDiabetesGuidelinesManagementMonitoringSide-effectsWeight gain
Type
Review
Information
European Psychiatry , Volume 26 , Issue 3 , April 2011 , pp. 144 - 158
Copyright
Copyright © Elsevier Masson SAS 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Alacqua, M, Trifiro, G, Arcoraci, V, Germano, E, Magazu, A, Calarese, T, et al.Use and tolerability of newer antipsychotics and antidepressants: a chart review in a pediatric setting. Pharm World Sci 2008;30(1):44–50.CrossRefGoogle Scholar
Allison, DB, Mentore, JL, Heo, M, Chandler, LP, Cappelleri, JC, Infante, MC, et al.Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686–1696.Google ScholarPubMed
Alvarez-Jimenez, M, Gonzalez-Blanch, C, Crespo-Facorro, B, Hetrick, S, Rodriguez-Sanchez, JM, Perez-Iglesias, R, et al.Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders. A systematic critical reappraisal. CNS Drugs 2008;22(7):547–562.Google ScholarPubMed
Aman, MG, De Smedt, G, Derivan, A, Lyons, B, Findling, RLRisperidone Disruptive Behavior Study Group Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159(8):1337–1346.CrossRefGoogle ScholarPubMed
Aman, MG, Arnold, LE, McDougle, CJ, Vitiello, B, Scahill, L, Davies, M, et al.Acute and long-term safety and tolerability of risperidone in children with autism. J Child. Adolesc Psychopharmacol 2005;15(6):869–884.Google Scholar
American Diabetes Association, , American Psychiatric Association, Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596–601.Google Scholar
Anderson, GM, Scahill, L, McCracken, JT, McDougle, CJ, Aman, MG, Tierney, E, et al.Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61(4):545–550.CrossRefGoogle Scholar
Armenteros, JL, Lewis, JE, Davalos, MRisperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 2007;46(5):558–565.CrossRefGoogle ScholarPubMed
Bansal, S, Buring, JE, Rifai, N, Mora, S, Sacks, FM, Ridker, PMFasting compared with non-fasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309–316.Google Scholar
Bhuvaneswar, CG, Baldessarini, RJ, Harsh, VL, Alpert, JEAdverse endocrine and metabolic effects of psychotropic drugs. CNS Drugs 2009;23(12):1003–1021.CrossRefGoogle ScholarPubMed
Boden, R, Haenni, A, Lindstrom, L, Sundstrom, JBiochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr Res 1152–32009 141–145.CrossRefGoogle ScholarPubMed
Buchanan, RW, Kreyenbuhl, J, Kelly, DL, Noel, JM, Boggs, DL, Fischer, BA, et al.Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71–93.Google ScholarPubMed
Buckley, PF, Miller, DD, Singer, BClinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281–288.CrossRefGoogle ScholarPubMed
Buitelaar, JK, van der Gaag, RJ, Cohen-Kettenis, P, Melman, CTA randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001;62(4):239–248.CrossRefGoogle ScholarPubMed
Cahn, W, Ramlal, D, Bruggeman, R, de Haan, L, Scheepers, FE, van Soest, MM, et al.Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. Tijdschr Psychiatr 2008;50(9):579–591.Google Scholar
Canitano, RClinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27(3):228–232.CrossRefGoogle ScholarPubMed
Cheng-Shannon, J, McGough, JJ, Pataki, C, McCracken, JTSecond-generation antipsychotic medications in children and adolescents. J Child. Adolesc Psychopharmacol 2004;14(3):372–394.Google Scholar
Cohen, D, Huinink, SAtypical-antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 2007;21(12):1035–1038.CrossRefGoogle ScholarPubMed
Cohen, D, Correll, CUSecond-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. J Clin Psychiatry 2009;70(5):765–766.Google ScholarPubMed
Correll, CU, Carlson, HEEndocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45(7):771–791.CrossRefGoogle ScholarPubMed
Correll, CU, Penzner, JB, Parikh, UH, Mughal, T, Javed, T, Carbon, M, et al.Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006;15(1):177–206.Google ScholarPubMed
Correll, CUWeight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007;46(6):687–700.CrossRefGoogle ScholarPubMed
Correll, CUAntipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008;47(1):9–20.Google ScholarPubMed
Correll, CUMonitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008;20(2):195–201.Google Scholar
Correll, CU, Manu, P, Olshanskiy, V, Napolitano, B, Kane, JM, Malhotra, AKCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302(16):1765–1773.CrossRefGoogle ScholarPubMed
Correll, CU, Sheridan, EM, DelBello, MPAntipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010;12(2):116–141.CrossRefGoogle ScholarPubMed
Croarkin, PE, Graham, JE, Mayes, TLNeuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008;69(7):1157–1165.Google ScholarPubMed
Daniels, SR, Greer, FRthe Committee on Nutrition Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122(1):198–208.Google ScholarPubMed
De Hert, M, Kalnicka, D, van Winkel, R, Hanssens, M, Van Eyck, L, Wampers, D, et al.Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2006;67(12):1889–1896.Google ScholarPubMed
De Hert, M, Schreurs, V, Sweers, K, Van Eyck, D, Hanssens, L, Sinko, S, et al.Typical and atypical antipsychotics differentially affect long-term incidence rates of metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 1011–32008 295–303.CrossRefGoogle ScholarPubMed
De Hert, M, Schreurs, V, Sweers, K, Vancamfort, D, Van Winkel, LMetabolic syndrome in people with schizophrenia: a review. Schizophr Res 2009;8(1):15–22.Google ScholarPubMed
De Hert, M, Dekker, JM, Wood, D, Kahl, KG, Holt, RIG, Moller, HJCardiovascular disease and diabetes in people with severe mental illness: Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24(6):412–424.CrossRefGoogle Scholar
De Hert, M, Vancampfort, D, Correll, CU, Mercken, V, Peuskens, J, Sweers, K, van Winkel, R, Mitchell, A. A systematic evaluation and comparison of the guidelines for screening and monitoring of cardiometabolic risk in people with schizophrenia. Br J Psychiatry 2010; submitted.Google Scholar
DelBello, MP, Adler, CM, Whitsel, RM, Stanford, KEStrakowski SM. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 2007;68(5):789–795.CrossRefGoogle ScholarPubMed
DelBello, MP, Versavel, M, Ice, K, Keller, D, Miceli, JTolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child. Adolesc Psychopharmacol 2008;18(5):491–499.CrossRefGoogle ScholarPubMed
DelBello, MP, Chang, K, Welge, JA, Adler, CM, Rana, M, Howe, M, et al.A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009;11(5):483–493.Google ScholarPubMed
DelBello, MP, Correll, CUPrimum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder. Bipolar Disorders 2010; 12: 113–115.Google ScholarPubMed
Dobbelaere M, De Hert M. Metabole en endocriene bijwerkingen van atypische antipsychotica bij kinderen en jongeren. Richtlijnen voor de klinische praktijk. Tijdschr Geneesk 2010;66(14–15):705–12.Google Scholar
Dubois, DToxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr 2005;17(2):227–233.CrossRefGoogle ScholarPubMed
Elman, I, Borsook, D, Lukas, SEFood intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006; 31: 2091–2120.CrossRefGoogle ScholarPubMed
Erickson, CA, Stigler, KA, Posey, DJ, McDougle, CJRisperidone in pervasive development disorder. Expert Rev Neurother 2005;5(6):713–719.CrossRefGoogle Scholar
Fernandez, JR, Redden, DT, Pietrobelli, A, Allison, DBWaist circumference percentiles in nationally representative samples of African-American. European-American, and Mexican-American children and adolescents. J Pediatr 2004;145(4):439–444.CrossRefGoogle ScholarPubMed
Findling, RL, McNamara, NK, Branicky, LA, Schluchter, MD, Lemon, E, Blumer, JLA double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000;39(4):509–516.Google ScholarPubMed
Findling, RLDosing of atypical antipsychotics in children and adolescents. J Clin Psychiatry 5Suppl. 62003 10–13.Google Scholar
Findling, RL, Kusumakar, V, Daneman, D, Moshang, T, De Smedt, G, Binder, CProlactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003; 6411: 1362–1369.CrossRefGoogle Scholar
Findling, RL, Robb, A, Nyilas, M, Forbes, RA, Jin, N, Ivanova, S, et al.A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165: 1432–1441.CrossRefGoogle ScholarPubMed
Findling, RL, Nyilas, M, Forbes, RA, McQuade, RD, Jin, N, Iwamoto, T, et al.Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009;70(10):1441–1451.CrossRefGoogle ScholarPubMed
Findling, RLAtypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 69Suppl. 42008 9–14.Google ScholarPubMed
Findling, RL, Johnson, JL, McClellan, J, Frazier, JA, Vitiello, B, Hamer, RM, et al.Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010;49(6):583–594.Google ScholarPubMed
Findling, R, Cavus, I, Pappadolulos, E, Backinsky, M, Schwartz, J, Vanderburg, DA placebo-controlled trial to evaluate the efficacy and safety of flexibly dosed oral ziprasidone in adolescent subjects with schizophrenia. Schizophr Res 1172–32010 437. doi: 10.1016/j.schres.2010.02.808CrossRefGoogle Scholar
Fleischhaker, C, Heiser, P, Hennighausen, K, Herpertz-Dahlmann, B, Holtkamp, K, Mehler-Wex, C, et al.Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 2006;16(3):308–316.Google ScholarPubMed
Floris, M, Lecompte, D, De Nayer, A, Mertens, C, Mallet, L, Vanden-driessche, F, et al.Antipsychotica en seksuele stoornissen. Neuron 72 Suppl.2001 1–9.Google Scholar
Food and Drug Administration. Pediatric indications. www.fda.gov/../CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM164423.pdf; accessed 01 06 2010.Google Scholar
Fraguas, D, Merchan-Naranjo, J, Laita, P, Perellada, M, Moreno, D, Ruiz-Sanco, A, et al.Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008;69(7):1166–1175.CrossRefGoogle ScholarPubMed
Gothefors, D, Adolfsson, R, Attvall, S, Erlinge, D, Jarbin, H, Lindstrom, K, et al.Swedish Clinical Guidelines Prevention and management of metabolic risk in patients with severe psychiatric disorders. Nord J Psychiatry 2010;64(5):294–302.Google ScholarPubMed
Haas, M, Delbello, MP, Pandina, G, Kushner, S, Van Hove, I, Augustyns, I, et al.Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009;11(7):687–700.CrossRefGoogle ScholarPubMed
Haas, M, Eerdekens, M, Kushner, S, Singer, J, Augustyns, I, Quiroz, J, et al.Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009;194(2):158–164.Google ScholarPubMed
Haas, M, Unis, AS, Armenteros, J, Copenhaver, MD, Quiroz, JA, Kushner, SFA 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009;19(6):611–621.CrossRefGoogle ScholarPubMed
Haddad, PM, Wieck, AAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291–2314.CrossRefGoogle ScholarPubMed
Hamner, MThe effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002;14(3):163–173.CrossRefGoogle ScholarPubMed
Hanssens, L, De Hert, M, Kalnicka, D, van Winkel, R, Wampers, M, Van Eyck, D, et al.Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 2007; 22: 43–49.Google ScholarPubMed
Haupt, DW, Rosenblatt, LC, Kim, E, Baker, RA, Whitehead, R, Newcomer, JWPrevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009;166(3):345–353.Google ScholarPubMed
Hellings, JA, Zarcone, JR, Crandall, K, Wallace, D, Schroeder, SRWeight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001;11(3):229–238.CrossRefGoogle Scholar
Hollander, E, Wasserman, S, Swanson, EN, Chaplin, W, Schapiro, ML, Zagursky, K, et al.A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child. Adolesc Psychophamacol 2006;16(5):541–548.CrossRefGoogle Scholar
Horan, MJ, Falkner, B, Kimm, SY, Loggie, JM, Prineas, RJ, Rosner, B, et al.Report of the second task force on blood pressure control in children 1987. Pediatrics 1987;79(1):1–25.Google Scholar
Hsu, C, Ried, LD, Bengtson, MA, Garman, PM, McConkey, JR, Rahnavard, FMetabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. J Am Pharm Assoc 2008;48(3):393–400.CrossRefGoogle ScholarPubMed
Jensen, PS, Buitelaar, J, Pandani, GJ, Binder, C, Haas, MManagement of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007;16(2):104–120.CrossRefGoogle ScholarPubMed
Jerell, JM, Bacon, J, Burgis, JT, Menon, SHyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. J Adolesc Health 2009;45(1):70–76.CrossRefGoogle Scholar
Kahn, RS, Fleischhaker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, et al.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371: 1085–1097.CrossRefGoogle Scholar
Kapetanovic, S, Simpson, GMReview of antipsychotics in children and adolescents. Expert Opin Pharmacother 2006;7(14):1871–1885.CrossRefGoogle ScholarPubMed
Kinon, BJ, Ahl, J, Liu-Seifert, H, Maguire, GAImprovement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006;31(5):77–588.CrossRefGoogle ScholarPubMed
Klein, DJ, Cottingham, EM, Sorter, M, Barton, BA, Morrison, JAA randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163(12):2072–2079.CrossRefGoogle ScholarPubMed
Kryzhanovskaya, L, Schulz, SC, McDougle, C, Frazier, J, Dittmann, R, Robertson-Plouch, C, et al.Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 60–70.CrossRefGoogle ScholarPubMed
Kryzhanovskaya, LA, Robertson-Plouch, CK, Xu, W, Carlson, JL, Merida, KM, Dittmann, RWThe safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 2009;70(2):247–258.CrossRefGoogle ScholarPubMed
Kumra, S, Oberstar, JV, Sikich, L, Findling, RL, McClellan, JM, Vinogradov, S, et al.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008;34(1):60–71.CrossRefGoogle ScholarPubMed
Lauwers, K, De Hert, MGlucose abnormalities in a non-psychotic patient treated with risperidone. J Am Acad Child Adolesc Psychiatry 2005; 44: 629–630.CrossRefGoogle Scholar
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31–41.CrossRefGoogle ScholarPubMed
Leucht, S, Komossa, K, Rummel-Kluge, C, CorvesF C., , Hunger, H, Schmid, F, et al.A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2008;166(2):152–163.CrossRefGoogle ScholarPubMed
Lindsay, RL, Leone, S, Aman, MGDiscontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr 2004;43(5):437–444.CrossRefGoogle ScholarPubMed
Lindström, E, Levander, SSertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother 2006;7(13):1825–1834.Google Scholar
Luby, J, Mrakotsky, C, Stalets, MM, Belden, A, Heffelfinger, A, Williams, M, et al.Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006;16(5):575–587.CrossRefGoogle ScholarPubMed
Marcus, RN, Owen, R, Kamen, L, Manos, G, McQuade, RD, Carson, WH, et al.A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48(11):1110–1119.CrossRefGoogle ScholarPubMed
Masi, G, Mucci, M, Pari, CChildren with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006;20(10):841–866.CrossRefGoogle ScholarPubMed
Maayan, L, Vakhrusheva, J, Correll, CUEffectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010;35(7):1520–1530.CrossRefGoogle ScholarPubMed
McCracken, JT, McGough, J, Shah, B, Cronin, P, Hong, D, Aman, MG, et al.Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347(5):314–321.CrossRefGoogle ScholarPubMed
McDougle, CJ, Stigler, KA, Erickson, CA, Posey, DJAtypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 69Suppl. 42008 15–20.Google ScholarPubMed
McEvoy, JP, Lieberman, JA, Perkins, DO, Hamer, RM, Gu, H, Lazarus, A, et al.Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164(7):1050–1060.CrossRefGoogle ScholarPubMed
Meyer, JM, Stahl, SMThe metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119(1):4–14.Google Scholar
Morrato, EH, Newcomer, JW, Allen, RR, Valuck, RPrevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008;69(2):316–322.CrossRefGoogle ScholarPubMed
Morrato, EH, Newcomer, JW, Kamat, S, Baser, O, Harnett, J, Cuffel, BMetabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32(6):1037–1042.Google ScholarPubMed
Morrato, EH, Druss, B, Hartung, DM, Valuck, RJ, Allen, R, Campagna, E, et al.Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen psychiatry 2010;67(1):17–24.CrossRefGoogle ScholarPubMed
Morrato, EH, Nicol, GE, Maahs, D, Druss, BG, Hartung, DM, Valuck, RJ, et al.Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 2010;164(4):344–351.CrossRefGoogle ScholarPubMed
Moreno, C, Merchán-Naranjo, J, Alvarez, M, Baeza, I, Alda, JA, Martínez-Cantarero, C, et al.Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 2010;12(2):172–184.CrossRefGoogle ScholarPubMed
Nagaraj, R, Shinghi, P, Malhi, PRisperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006;21(6):450–455.CrossRefGoogle ScholarPubMed
Nasrallah, HA, Meyer, JM, Goff, DC, McEvoy, JP, David, SM, Stroup, TS, et al.Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 861–32006 15–22.Google ScholarPubMed
Nasrallah, HAAtypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13(1):27–35.CrossRefGoogle ScholarPubMed
Newcomer, JW, Nasrallah, HA, Loebel, ADThe atypical antipsychotic therapy and metabolic issues national survey. J Clin Psychopharmacol 2004; 24: 1–6.Google ScholarPubMed
Nicol, G, Haupt, D, Flavin, K, Schweiger, J, Hessler, M, Hessler, E, et al.Preliminary results of the MEAC study: metabolic effects of antipsychotics in children. Schizophr Bull 35Suppl. 12009 32Google Scholar
Nielsen, J, Skadhede, S, Correll, CUAntipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 201010.1038/npp.2010.78CrossRefGoogle ScholarPubMed
Nordestgaard, BG, Benn, M, Schnohr, P, Tybjaerg-Hansen, ANonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299–308.Google ScholarPubMed
Olfson, M, Blanco, C, Liu, L, Moreno, C, Laje, GNational trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63(6):679–685.CrossRefGoogle ScholarPubMed
Olfson, M, Crystal, S, Huang, C, Gerhard, TTrends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 2010;49(1):13–23.Google ScholarPubMed
Overbeek, WA, de Vroede, MA, Lahuis, BE, Hillegers, MH, de Graeff-Meeder, ERAntipsychotics and metabolic abnormalities in children and adolescents: a review of the literature and some recommendations. Tijdschr Psychiatr 2010;52(5):311–320.Google ScholarPubMed
Owen, R, Sikich, L, Marcus, R, Corey-Lisle, P, Manos, G, McQuade, RD, et al.Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124: 1533–1540.Google ScholarPubMed
Panagiotopoulos, C, Ronsley, R, Elbe, D, Davidson, J, Smith, DHFirst do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010;19(2):124–137.Google ScholarPubMed
Pappagallo, M, Silva, RThe effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 2004;14(3):359–371.CrossRefGoogle ScholarPubMed
Patel, JK, Buckley, PF, Woolson, S, Hamer, RM, McEvoy, JP, Perkins, DO, et al.Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 1111–32009 9–16.CrossRefGoogle ScholarPubMed
Rani, F, Murray, ML, Byrne, PJ, Wong, ICKEpidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008; 121: 1002–1009.CrossRefGoogle ScholarPubMed
Remschmidt, K, Hennighausen, K, Clement, HW, Heiser, P, Schulz, EAtypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9Suppl. 12000 9–19.Google ScholarPubMed
Roke, Y, van Harten, PN, Boot, AM, Buitelaar, JKAntipsychotic medication in children and adolescents: a descriptive review on the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 2009;19(4):403–414.CrossRefGoogle ScholarPubMed
Sallee, FR, Kurlan, R, Goetz, CG, Singer, H, Scahill, L, Law, G, et al.Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000;39(3):292–299.Google ScholarPubMed
Scahill, L, Leckman, JF, Schultz, RT, Katsovich, L, Peterson, BSA placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60(7):1130–1135.CrossRefGoogle ScholarPubMed
Simon, V, van Winkel, R, De Hert, MAre weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70(7):1041–1050.CrossRefGoogle ScholarPubMed
Shea, S, Turgay, A, Carroll, A, Schulz, M, Orlik, H, Smith, I, et al.Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004;114(5):e634–e641.Google ScholarPubMed
Shin, L, Bregman, H, Breeze, JL, Noyes, N, Frazier, JAMetformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 2009;19(3):275–279.CrossRefGoogle ScholarPubMed
Sikich, L, Hamer, RM, Bashford, RA, Sheitman, BB, Lieberman, JAA pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29(1):133–145.Google ScholarPubMed
Sikich, L, Frazier, JA, McClellan, J, Findling, RL, Vitiello, B, Ritz, L, et al.Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008;165(11):1420–1431.CrossRefGoogle ScholarPubMed
Snyder, R, Turgay, A, Aman, M, Binder, C, Fisman, S, Carroll, AEffects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41(9):1026–1036.CrossRefGoogle ScholarPubMed
Spina, E, Zoccali, RSertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin Drug Metab Toxicol 2008;4(5):629–638.CrossRefGoogle ScholarPubMed
Stigler, KA, Potenza, MN, Posey, DJ, McDougle, JWeight gain associated with atypical antipsychotic use in children and adolescents. Paediatr Drugs 2004;6(1):33–44.CrossRefGoogle ScholarPubMed
Swadi, HS, Craig, BJ, Pirwani, NZ, Black, VC, Buchan, JC, Bobier, CMA trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. Int Clin Psychopharmacol 2010;25(1):1–6.CrossRefGoogle ScholarPubMed
Tarricone, I, Gozzi, BF, Serretti, A, Grieco, D, Berardi, DWeight gain in antipsychotic-naïve patients: a review and meta-analysis. Psychol Med 2010; 40: 187–200.Google ScholarPubMed
Tohen, M, Kryzhanovskaya, L, Carlson, G, Delbello, M, Wozniak, J, Kowatch, R, et al.Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;164(10):1547–1556.Google ScholarPubMed
Tramontina, S, Zeni, CP, Ketzer, CR, Pheula, GF, Narvaez, J, Rohde, LAAripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009;70(5):756–764.CrossRefGoogle ScholarPubMed
Vancampfort, D, Knapen, J, Probst, M, van Winkel, R, Deckx, S, Maurissen, K, et al.Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res 2010;177(3):271–279.CrossRefGoogle Scholar
Van Bellinghen, M, De Troch, CRisperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001;11(1):5–13.CrossRefGoogle ScholarPubMed
Varley, K, McClennan, JImplications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA 2009;302(16):1811–1812.Google ScholarPubMed
Vieweg, WV, Sood, AB, Pandurangi, A, Silverman, JJNewer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand 2005;111(3):177–184.CrossRefGoogle ScholarPubMed
Weinstein, LS, Xie, T, Wang, J, Chen, MThe role of GNAS and other imprinted genes in the development of obesity. Int J Obes 2010;34(1):6–17.Google ScholarPubMed
Zimmet, P, Alberti, G, Kaufman, F, Tajima, N, Silink, M, Arslanian, S, et al.The metabolic syndrome in children and adolescents. Lancet 2007; 369: 2059–2061.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.